Kaposi's sarcoma
MONDO:0005055A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).
Also known as: KS, Kaposi sarcoma, Kaposi's sarcoma, Kaposi's sarcoma (disease), Kaposi's sarcoma of anus, Kaposi's sarcoma of central nervous system, Kaposi's sarcoma of esophagus, Kaposi's sarcoma of gastrointestinal sites
2862 clinical trials for this condition and its sub-types, 45 tagged with Kaposi's sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Kaposi's sarcoma
-
Classic Kaposi sarcoma 3 trials
-
Endemic Kaposi sarcoma 1 trial
-
Iatrogenic Kaposi's sarcoma 1 trial
-
Colorectal Kaposi sarcoma 0 trials
2 sub-types
- Colon Kaposi sarcoma 0 trials
- Rectum Kaposi sarcoma 0 trials
-
Can a smaller dose of this cancer drug still work? new trial aims to find out
Disease control Not yet recruitingThis phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could a common heart drug treat kaposi sarcoma?
Disease control Not yet recruitingThis phase 2 trial tests whether propranolol, a drug usually used for high blood pressure, can treat Kaposi sarcoma. About 25 children and adults will take propranolol pills for up to 24 weeks. Researchers will measure how many participants see their tumors shrink or disappear, a…
Phase 2 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Experimental drug shows promise for kaposi sarcoma lesions
Disease control Not yet recruitingThis study tests a drug called nirogacestat in 28 people with Kaposi sarcoma skin tumors. The drug blocks a protein that helps tumors grow, aiming to shrink lesions and stop them from spreading. While not a cure, it may offer a new way to control the disease in people who haven't…
Phase 2 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for HIV patients: cheaper chemo may work just as well for kaposi sarcoma
Disease control Not yet recruitingThis study tests whether two different chemotherapy drugs, paclitaxel and pegylated liposomal doxorubicin, work equally well for treating Kaposi sarcoma in people living with HIV in sub-Saharan Africa. About 130 participants will receive one of the drugs every three weeks for six…
Phase 3 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
HIV and cancer: study seeks to uncover hidden risk factors
Knowledge-focused Not yet recruitingThis study looks at how certain cancers develop in people with HIV and what factors might increase their risk. Researchers will analyze medical data from 1,000 HIV-positive adults to track which types of cancer occur most often and why. The goal is to improve early detection and …
Sponsor: Shenzhen Third People's Hospital • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC